In a bid to bolster its neurology pipeline, Astellas has entered into a collaboration agreement with Taysha Gene Therapies in a deal worth up to US$50 M. Astellas will be granted access to TSHA-102 and TSHA-120 for Rett syndrome and giant axonal neuropathy, respectively; both assets are developed using Taysha’s miRARE technology platform. Interestingly, the deal comes four months after Astellas announced that the US FDA has placed a clinical hold on the FORTIS Phase I/II trial studying gene therapy, AT845, in adults with late-onset Pompe disease following a serious adverse event.